Clinical Utility of U‐p53AZ as a prognostic biomarker for the prediction of progression rate, in individuals with early stages of Alzheimer’s Disease
Shmuel Agus, Simona Piccirella, Abe Durrant, Garrett B Duncan, Samuel P. Dickson, Suzanne B. Hendrix, Paul Kinnon · 2025
Read Clinical Utility of U‐p53AZ as a prognostic biomarker for the prediction of progression rate, in individuals with early stages of Alzheimer’s Disease by Shmuel Agus, Simona Piccirella, Abe Durrant, Garrett B Duncan, Samuel P. Dickson, Suzanne B. Hendrix, Paul Kinnon (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713905.txt.
Description
Shmuel Agus and co-authors tested a blood marker that may forecast how fast early Alzheimer's disease will advance, in work published in 2025. Trials and clinics both need to know who will worsen quickly, and who will stay stable for years. The marker, called U-p53AZ, comes from a form of a well-known cell protein. The team drew on 629 people from two aging studies in Australia and the United States.
The group included people with the disease, people with mild memory problems, and people with normal thinking. The marker alone foretold a diagnosis six years later with very high accuracy, and it beat scans and spinal fluid tests in the team's checks. It also flagged fast advancers over two years with strong accuracy. The authors say the test could sharpen screening for trials and speed early care to those who need it most.
Catalog record
| CREATOR | Shmuel Agus, Simona Piccirella, Abe Durrant, Garrett B Duncan, Samuel P. Dickson, Suzanne B. Hendrix, Paul Kinnon |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |